HELP US PREVENT PANCREATIC CANCER

The CAncer of the Pancreas Screening-5 (CAPS5) Study at Dana-Farber Cancer Institute is enrolling patients with a family history of pancreatic cancer and/or specific gene mutations. The CAPS5 study is being done to see if we can detect pancreatic cancer before clear signs or symptoms of the disease. In addition, we are looking for better tests for the diagnosis of pancreatic cancer.

ELIGIBLE PARTICIPANTS WOULD:*

- Be undergoing clinical pancreas screening
- Have a mutation that increases your risk of pancreatic cancer and/or
- Have a family history of pancreatic cancer

*Other eligibility criteria may be determined by phone or in-person

WHAT WILL HAPPEN IF YOU JOIN?
You would:
- Be followed for 5 years
- Give a blood sample on the day of your pancreas screening procedure

This study may or may not provide direct benefit but we hope it can benefit those in the future. Whether or not you decide to join the study, your current clinical care will not be affected.

Please call or email the research coordinator below for more information about the CAPS5 research study:

Audrey Madigan  Sapna Syngal, M.D., M.P.H
Research Coordinator Dana-Farber Cancer Institute
Office: (617) 632-3354  Principal Investigator
audreyp_madigan@dfci.harvard.edu

DANA-FARBER
CANCER INSTITUTE